Abstract
Using PICK1 as an example this review highlights PDZ domains support a repertoire of protein-protein interactions that regulate the subcellular localisation and function of receptors, ion channels and enzymes. PICK1 is a 416 amino acid protein that contains a PDZ domain, a coiled-coil motif/arfaptin homology domain and an acidic c-terminal. Nearly all proteins thus far reported to interact with PICK1 do so via its single PDZ domain. PICK1 self-associates via its coiled-coil motif and together with its PDZ domain has potential to act as a scaffolding protein. This molecule was first identified as a protein interacting with Cα-kinase (PICK1) and interacts with several members of the glutamate receptor family and receptor tyrosine kinases. The PDZ domain of PICK1 has since been shown to interact with a plethora of proteins including dopamine transporter, prolactin-releasing peptide receptor, ion channels BNaC1/ASIC and many more. The single PDZ domain of PICK1 interacts with a network of proteins that is pivotal in processes such as synaptic plasticity, development and neural guidance as well as many diseased states. The proteins that interact with PICK1 and the functional roles of its PDZ domain are discussed and illustrated are ways to regulate PDZ protein-protein interactions.
Keywords: PICK1, PDZ domain, PDZ binding motif, protein-protein interactions
Current Topics in Medicinal Chemistry
Title: PDZ Domain Protein-Protein Interactions: A Case Study with PICK1
Volume: 7 Issue: 1
Author(s): Kumlesh K. Dev
Affiliation:
Keywords: PICK1, PDZ domain, PDZ binding motif, protein-protein interactions
Abstract: Using PICK1 as an example this review highlights PDZ domains support a repertoire of protein-protein interactions that regulate the subcellular localisation and function of receptors, ion channels and enzymes. PICK1 is a 416 amino acid protein that contains a PDZ domain, a coiled-coil motif/arfaptin homology domain and an acidic c-terminal. Nearly all proteins thus far reported to interact with PICK1 do so via its single PDZ domain. PICK1 self-associates via its coiled-coil motif and together with its PDZ domain has potential to act as a scaffolding protein. This molecule was first identified as a protein interacting with Cα-kinase (PICK1) and interacts with several members of the glutamate receptor family and receptor tyrosine kinases. The PDZ domain of PICK1 has since been shown to interact with a plethora of proteins including dopamine transporter, prolactin-releasing peptide receptor, ion channels BNaC1/ASIC and many more. The single PDZ domain of PICK1 interacts with a network of proteins that is pivotal in processes such as synaptic plasticity, development and neural guidance as well as many diseased states. The proteins that interact with PICK1 and the functional roles of its PDZ domain are discussed and illustrated are ways to regulate PDZ protein-protein interactions.
Export Options
About this article
Cite this article as:
Dev K. Kumlesh, PDZ Domain Protein-Protein Interactions: A Case Study with PICK1, Current Topics in Medicinal Chemistry 2007; 7 (1) . https://dx.doi.org/10.2174/156802607779318343
DOI https://dx.doi.org/10.2174/156802607779318343 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Unexpected Effects of Acetylcholine Precursors on Pilocarpine Seizure- Induced Neuronal Death
Current Neuropharmacology Meet Our Editorial Board Member
Current Aging Science Melatonin, its Metabolites and its Synthetic Analogs as Multi-Faceted Compounds: Antioxidant, Prooxidant and Inhibitor of Bioactivation Reactions
Current Medicinal Chemistry Editorial [Hot Topic: Neurotransmitter Transporters Guest Editor: Dr. Anders A. Jensen ]
Current Topics in Medicinal Chemistry The Role of SPECT and MRI for Pre and Postoperative Evaluation of Childhood Moyamoya Disease: Case Report and Review of Literature
Current Medical Imaging Molecular Docking Studies and Inhibition Properties of Some Antineoplastic Agents against Paraoxonase-I
Anti-Cancer Agents in Medicinal Chemistry Glutamate in CNS Neurodegeneration and Cognition and its Regulation by GCPII Inhibition
Current Medicinal Chemistry SiRNA Mediated Gene Silencing: Hurdles, Strategies and Applications
Pharmaceutical Nanotechnology The Large Conductance Calcium- and Voltage-activated Potassium Channel (BK) and Epilepsy
CNS & Neurological Disorders - Drug Targets Therapeutic Hypothermia in Brain Injuries and Related Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Regulatory Cascade of Neuronal Loss and Glucose Metabolism
CNS & Neurological Disorders - Drug Targets Patented Small Molecules Used for Reprogramming
Recent Patents on Regenerative Medicine Cognition-Enhancing Drugs in Mild Cognitive Impairment (MCI) and Alzheimers Disease (AD): An Update [1]
Medicinal Chemistry Reviews - Online (Discontinued) The Enigmatic Drug Binding Site for Sodium Channel Inhibitors
Current Molecular Pharmacology Design, Synthesis, Anticonvulsant Activity, Preclinical Study and Pharmacokinetic Performance of N-{[3-(4-chlorophenyl)-4-oxo-3, 4-dihydroquinazolin- 2-yl] methyl}, 2-[(2-isopropyl-5-methyl) 1-cyclo Hexylidene] Hydrazinecarboxamide
Central Nervous System Agents in Medicinal Chemistry Human Microdialysis
Current Pharmaceutical Biotechnology Capillary Electrophoresis Interfaced with a Mass Spectrometer (CE-MS): Technical Considerations and Applicability for Biomarker Studies in Animals
Current Protein & Peptide Science History and Therapeutic Use of MAO-A Inhibitors: A Historical Perspective of MAO-A Inhibitors As Antidepressant Drug
Current Topics in Medicinal Chemistry Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder
Current Pharmaceutical Design